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Abstract
Background: Research suggests that economic recessions might be associated with a higher use of psychotropic
drugs, but literature is scarce and contradictory in identifying the most vulnerable groups. This study aims to assess
possible changes in the use of psychotropic drugs due to the economic recession in Portugal, by comparing self-
reported consumption in 2008/09 and 2015/16.
Methods: Data from the World Mental Health Survey Initiative Portugal (2008/09) and the National Mental Health
Survey Follow-Up (2015/16) were used (n = 911). McNemar’s tests were performed to estimate changes in
consumption of any psychotropic drug and of antidepressants, anxiolytics, and hypnotics/sedatives. Multiple
Generalised Estimating Equations models with interaction effects were used to estimate the population odds of
consuming psychotropic drugs according to year, gender and age.
Results: An increase of 6.74% was estimated in the consumption of psychotropic drugs from 2008/09 to 2015/16.
Population odds of consuming any psychotropic drugs in 2015/16 were estimated to be 1.5 times higher than in
2008/09 (OR = 1.50;95%CI:1.13–2.01), particularly for hypnotics/sedatives (OR = 1.60;95%CI:1.14–2.25). Women and
older individuals presented higher odds of consuming any psychotropic drugs (OR = 2.79;95%CI:2.03–3.84, and
OR = 1.80;95%CI:1.28–2.54), after adjusting for year of assessment and education. However, when evaluating the
interaction effect of the year with gender and age, men and younger individuals reported higher odds of
consuming any psychotropic drugs in 2015/16, when compared to 2008/09 (OR = 1.85;95%CI:1.08–3.17, and OR =
1.95;95%CI:1.32–2.90, respectively).
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Conclusions: The findings indicate that the period of economic recession was associated with an increased risk of
psychotropic drugs use in Portugal. Consumption of psychotropic drugs remained higher among women and older
individuals, but the results suggest that the economic crisis had a disproportionate impact on men and younger
individuals. This identification of the most vulnerable population groups is useful to design effective and targeted
public health interventions aimed at alleviating the effects of economic recessions.
Keywords: Psychotropic drugs, Economic recession, Gender, Age, Public health
Background
The 2008 global financial crisis precipitated the most se-
vere economic recession to date, surpassing the Great
Depression of the 1930s [1, 2]. Among European countries,
Portugal was particularly affected, in terms of decline in
gross domestic product (GDP), rise of unemployment rates,
and government deficit [3, 4]. As part of the austerity pol-
icies, large cuts to public expenditure and to health and so-
cial budgets were made, and savings of €670 million were
demanded from the Portuguese National Health Service,
targeting care and drug expenditure, prescriptions, work-
force, and user charges [3]. A mix of cost-containment pol-
icies in the pharmaceutical sector was implemented, aiming
to reduce the public expenditure on drugs from 1.55% of
GDP in 2010 to 1% by the end of 2013 [3, 5, 6]. Measures
included increase in co-payments for pharmaceuticals, gen-
eric drugs promotion campaigns, electronic prescription,
and discounts granted to the public payer [3, 6, 7]. These
measures tend to shift the cost-burden to those who
needed medicines, in a country where out-of-pocket pay-
ments already represented an important part of total health
care expenditure [8, 9]. Concerns arose about the unin-
tended risk of less equitable access to needed medicines
and “cost-related non-adherence” [10, 11].
The impact of economic crises on the use of mental
health care is expected to be mixed. On the one hand,
demand for mental health is likely to increase, and sub-
stantial research has shown that periods of economic re-
cession can be damaging to mental health due to risk
factors such as economic adversity (e.g. job and income
loss) [12–15]. On the other hand, mental health systems
may not meet this growing need, due to fiscal austerity
measures that reduce availability and affordability of ser-
vices [12]. Most findings suggest that during recessions
prescriptions for psychotropic drugs rise [16–19], in-
cluding those to treat depressive and anxiety disorders
[18, 20–23]. Some studies didn’t find this association
[24, 25], but found a widening of consumption differ-
ences according to gender and age [25].
Several studies have examined patterns and trends of
consumption of psychotropic drugs over the past de-
cades, showing overall increases in utilization, consist-
ently higher among women and with older age, lower
income and educational levels, and mental health care
use within the past 12-months [26]. Some possible ex-
planations for gender differences in the use of psycho-
tropic drugs were pointed out, such as representing a
proxy for differences in the prevalence of mental disorders
in women and men, reflecting the degree of gender inequal-
ity within a country, or denoting different healthcare-
seeking behaviour, prescription preferences by mental
health professionals and services, or health expenditure al-
located to mental health care [26]. Among classes of psy-
chotropic drugs, antidepressants are the most widely and
increasingly prescribed drugs, particularly among women
and across older age groups [27].
Little is known about the impact of the Great Recession
on changes in the pattern of consumption of psychotropic
drugs in Portugal. Compared to other European countries,
Portugal has higher rates of consumption of psychotropic
drugs [28, 29], which may be partly explained by the fact
that the country has one of the highest prevalences of men-
tal disorders in Europe [30, 31]. This high consumption has
been recognized as a public health challenge [28], as it is
largely based on anxiolytics, and hypnotics/sedatives. Avail-
able official data show a continuous increase in the pre-
scription and dispensing of all subgroups of psychotropic
drugs in the National Health Service between 2000 and
2016, especially antidepressants and antipsychotics [28, 32].
This may reflect a greater accessibility to medicines, longer
use, approval of new therapeutic indications [28], and the
deterioration of the population’s mental health, particularly
common mental disorders. The increase in the prescription
and utilization of psychotropic drugs since the beginning of
the economic recession suggests that the worsening of
mental health problems and the need for medication
exceeded the impact of changes in affordability. Available
research evaluating the impact of pharmaceutical sector
policies during this period focuses exclusively on consump-
tion of antipsychotic drugs [7].
Given the scarce evidence and the public health im-
portance of this topic in the Portuguese context, this
study aims to assess possible changes in the use of psy-
chotropic drugs indicated for the treatment of common
mental disorders, the clinical situations predictably most
affected by economic recessions [13, 14]. Self-reported
consumption of psychotropic drugs, including antide-
pressants, anxiolytics, and hypnotics/sedatives, was
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evaluated before and after the economic recession in
Portugal, accounting for gender and age differences. This
research adds to the existing literature by comparing the
use of psychotropic drugs by the same individuals before
and after an economic recession, and the findings may
provide valuable insights for targeted interventions and
policy-making.
Methods
Design and study sample
This study used data from the National Mental Health
Survey (T0) and the National Mental Health Survey
Follow-Up (T1).
National Mental Health Survey (T0)
The National Mental Health Survey was conducted in
2008/09 as part of the World Mental Health Survey
(WMHS) Initiative. This nationally representative cross-
sectional survey was based on a stratified multistage
clustered area probability household sample of Portuguese-
speaking adults, aged 18 years or above, residing in perman-
ent dwellings in the country’s mainland.
A response rate of 57.3% was obtained, similar to the re-
sults in Belgium, France, Germany, and the Netherlands.
The survey was administered by trained lay interviewers
with a computer-assisted personal interview in a face-to-
face setting, and the questionnaire was divided into two
parts to reduce respondent burden. Part I was adminis-
tered to all participants (n = 3849), and Part II to partici-
pants with criteria for any mental disorder, and to a
probability sample of 25% randomly selected participants
who did not meet these criteria (n = 2060). Part I included
core diagnostic assessment of mental disorders, and Part
II included the assessment of additional mental disorders,
correlates and consequences of mental disorders, self-
reported chronic conditions, and use of services.
Two different weightings were considered. Weighting
procedures were applied to Part I data to adjust differen-
tial probabilities of selection between and within house-
holds, non-response bias and discrepancies between the
sample and the sociodemographic and geographic distri-
bution of the Portuguese census population. Part II data
were additionally weighted to adjust for differential sam-
pling of Part I participants into Part II [33].
Informed consent was obtained from all respondents
and all procedures were approved by the Ethics Com-
mittee of the Nova Medical School, Nova University of
Lisbon (ref.: 10/2008). Further details regarding the
study design, fieldwork procedures, and methodology
can be found elsewhere [33].
National Mental Health Survey Follow-up (T1)
In 2015/16, a follow-up of the National Mental Health
Survey was conducted to compare epidemiological data
on mental disorders, socioeconomic conditions, and use
of services before and after the economic recession. In-
formed consent was obtained from participants and all
procedures were approved by the Ethics Committee of
the Nova Medical School, Nova University of Lisbon
(ref.: 16/2015/CEFCM).
Fieldwork procedures were similar to those of the
WMHS. All individuals with a mental disorder diagnosis
in T0 and a 20% random sample of those without a diag-
nosis that had participated in Part II were recruited to
the follow-up survey (n = 911). A new weighting was
created based on the Part II weighting previously de-
scribed, to adjust for the differential probability of selec-
tion to the follow-up [34].
Measurements
Assessment of psychotropic drugs
The use of any psychotropic drugs in the previous 12
months, regardless of the presence of a clinical diagno-
sis, was evaluated in both T0 and T1. In both T0 and
T1, participants were asked the same question: “Did you
take any type of prescription medicine in the past 12
months for problems with your emotions, substance use,
energy, concentration, sleep, or ability to cope with
stress? Include medicines even if you took them only
once”. If so, participants were requested to indicate
which of the medicines they had taken from a long list
that included 1) antidepressants, 2) anxiolytics, and 3)
hypnotics/sedatives.
Sociodemographic characteristics
Participants’ sociodemographic characteristics, including
gender, age, and educational level, were evaluated at
baseline (T0). Age was assessed as a continuous variable
and dichotomized into two categories (18–49 years of
age versus > 50 years of age at the baseline). Education is
widely used as an indicator of socioeconomic position in
epidemiological studies [35], and the number of years of
educational attainment at the baseline (continuous vari-
able) was used to adjust multivariate models.
Statistical analysis
Frequency tests and McNemar’s tests for comparing mar-
ginal proportions were used for descriptive analyses.
Multiple Generalised Estimating Equations (GEE) models
were performed to estimate the population odds of con-
suming psychotropic drugs according to year, gender and
age groups. The correlation between the observations
among the paired measurements were considered as hav-
ing an exchangeable structure, meaning that the correla-
tions are identical but unknown [36].
The choice of the GEE models in this study was made
since the same individuals were considered in T0 and
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T1 (i.e. repeated measures) and because of the interest
in evaluating changes at the population level.
Odds ratios (OR) were estimated and interpreted at
specific levels of the main effects and interaction terms
considering differences in psychotropic drugs in both
periods according to gender and age. The standard er-
rors of the odds ratio estimates, used to obtain the confi-
dence intervals, employed values from the variance-
covariance matrix of the corresponding model fits. Esti-
mates were weighted according to the characteristics of
the study, as previously explained. A significance level of
α = 0.05 was used throughout the analysis. Data analysis
was conducted using R version 3.5.1. The R package gee-
pack was used to fit the GEE models [37, 38].
Results
The characteristics of the study sample at the baseline
are presented in Table 1.
The results of the McNemar’s tests, presented in
Table 2, indicate a significant increase in the percentage
of individuals consuming any psychotropic drugs be-
tween T0 and T1 (6.74; 95%CI: 3.89–9.6). Statistically
significant increases in the consumption of any psycho-
tropic drugs were found among men (7.97%; 95%CI:
4.23–11.71), women (5.54%; 95%CI: 1.25–9.84), and
younger individuals (9.85%; 95%CI: 5.9–13.79). Regard-
ing specific types of psychotropic drugs, an estimated
increase of 2.80% in the percentage of individuals report-
ing consumption of antidepressants was found from T0
to T1 (95%CI: 0.65–4.95). A statistically significant in-
crease was also found for women, estimated around
3.75% (95%CI: 0.18–7.33). No statistically significant in-
crease in the consumption of antidepressants was found
among men, but the confidence interval obtained is
marginally close to zero on its lower margin, which may
suggest a tendency for an increase among this group. A
statistically significant increase between T0 and T1 was
also found in the percentage of younger individuals
consuming antidepressants, estimated at around 4.72%
(95%CI: 1.81–7.62). The percentage of individuals
reporting consumption of hypnotics/sedatives had a sta-
tistically significant increase from T0 to T1, estimated at
around 4.81% (95%CI: 2.30–7.31). The percentage of
males reporting use of hypnotics/sedatives was also esti-
mated to have increased around 7.30% (95%CI: 3.96–
10.62). This tendency was also found in the percentage
of younger individuals (18–49 years at baseline), esti-
mated at around 5.84% (95%CI: 2.72–8.95). A statisti-
cally significant increase between T0 and T1 was found
in the percentage of younger individuals (18–49 years at
baseline) taking anxiolytics, estimated at around 4.73%
(95%CI: 1.21–8.24).
The results of the GEE models, presented in Table 3,
indicate that the population odds of consuming any psy-
chotropic drugs in T1 were estimated to be 1.5 times
higher compared to T0 (OR = 1.50; 95%CI: 1.13–2.01),
after adjusting for age, gender and education. Likewise,
the population odds of consuming hypnotics/sedatives
in T1 were estimated to be 1.6 times higher than in T0
(OR = 1.60; 95%CI: 1.14–2.25). Compared to men,
women had an estimated 2.8 times higher odds of con-
suming any medication (OR = 2.79; 95%CI: 2.03–3.84),
3.5 times higher odds of consuming antidepressants
(OR = 3.49; 95%CI: 2.25–5.43), 1.9 times higher odds of
consuming anxiolytics (OR = 1.89; 95%CI: 1.27–2.81),
and 2.4 times higher odds of consuming hypnotics/seda-
tives (OR = 2.40; 95%CI: 1.64–3.51), adjusting for age,
year and education.
Compared to younger individuals, older individuals
had an estimated 1.8 times higher odds of consuming
any medication (OR = 1.80; 95%CI: 1.28–2.54), anxio-
lytics (OR = 1.84; 95%CI: 1.21–2.79), and hypnotics/seda-
tives (OR = 1.85; 95%CI: 1.23–2.79), adjusting for
gender, year and education.
The interaction effects of gender and year in the popu-
lation odds of consuming psychotropic drugs, presented
in Table 4, showed that the male population odds of
consuming any psychotropic drugs in T1 were estimated
to be 1.85 times higher when compared to T0 (OR =
1.85; 95% CI:1.08–3.17) and the odds of the male popu-
lation consuming hypnotics/sedatives were estimated to
be 2.60 times higher in T1 than in T0 (OR = 2.60; 95%
CI: 1.36–4.98). The female population odds of consum-
ing any psychotropic drugs in T1 were estimated to be
1.3 times higher than in T0, however without statistical
significance (p > 0.05). The results also showed that the
younger group population odds of consuming any psy-
chotropic drugs (OR = 1.95; 95% CI:1.32–2.90), antide-
pressants (OR = 1.68; 95% CI:1.05–2.68), and hypnotics/
sedatives (OR = 2.16; 95% CI: 1.34–3.47) in T1 were
higher when compared to the equivalent consumption
in T0. No statistically significant results were found in
the older population group.






18–49 at baseline 545 (59.8)
≥ 50 at baseline 366 (40.2)
Mean (sd) a
Education (years) 9.22 (4.83)
a%, N unweighted; means and standard deviations (sd) estimated with
weighting from follow-up study
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Discussion
This study provides an assessment of self-reported con-
sumption of psychotropic drugs in 2008/2009 and in
2015/16, which includes the period of economic reces-
sion in Portugal, recognizing the importance of gender
and age differences. The results show a significant in-
crease in the use of psychotropic drugs during this
period, particularly regarding the consumption of hyp-
notics/sedatives. These findings are in line with other
studies about the impact of economic recessions on the
consumption of psychotropic drugs [20, 22, 23]. This in-
crease may reflect a deterioration of the mental health of
the Portuguese population during the economic reces-
sion, as found in epidemiological studies in other coun-
tries [13, 14], or higher perceived need of care [39–41].
The results are consistent with other research indicat-
ing that women consistently use psychotropic drugs
more often than men [26, 27], and these gender differ-
ences were found for all the categories of psychotropic
drugs [26]. Higher consumption of psychotropic drugs
Table 2 Estimates of the use of psychotropic drugs in 2009, 2015 and the difference between those years
Use in 2009 (%) Use in 2015 (%) Difference between 2009 and 2015 and respective 95%CI (%)a
Any psychotropic drug
Population 20.9 28.2 6.74 (3.89–9.60)b
Gender
Men 11.5 19.1 7.97 (4.23–11.71)b
Women 30.9 37.2 5.54 (1.25–9.84)b
Age
18–49 at baseline 15.3 25.7 9.85 (5.90–13.79)b
≥ 50 at baseline 29.8 32.0 2.21(−1.76–6.18)
Antidepressants
Population 8.3 11.0 2.80 (0.65–4.95)b
Gender
Men 3.6 5.4 1.81 (−0.53–4.17)
Women 12.9 16.6 3.75 (0.18–7.33)b
Age
18–49 at baseline 7.9 12.5 4.72 (1.81–7.62)b
≥ 50 at baseline 9.1 8.9 0.28 (−3.40–2.84)
Anxiolytics
Population 12.3 14.5 2.36 (−0.32–5.04)
Gender
Men 7.8 11.4 3.41 (−0.05–6.87)
Women 16.9 17.7 1.33 (−2.75–5.42)
Age
18–49 at baseline 8.9 13.4 4.73 (1.21–8.24)b
≥ 50 at baseline 17.4 16.3 1.11 (−5.24–3.03)
Hypnotics/sedatives
Population 11.4 16.9 4.81 (2.30–7.31)b
Gender
Men 5.4 12.6 7.30 (3.96–10.62) b
Women 17.6 21.1 2.21(−1.51–5.92)
Age
18–49 at baseline 7.0 13.8 5.84 (2.72–8.95)b
≥ 50 at baseline 18.2 21.5 3.31 (−0.86–7.47)
a McNemar’s test
% weighted
bStatistical significance considered when 95%CI does not contain 0
CI Confidence interval
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was found in the older age group, also in line with stud-
ies that show higher prescription levels with increasing
age [27].
However, it is important to highlight that males and
younger individuals appear to have been affected dispro-
portionately by the recession in terms of consumption of
psychotropic drugs, since the odds of consuming any
medication in 2015/16, when compared to 2008/09, were
found to be higher in both groups. Higher odds of using
hypnotics/sedatives in 2015/16 were found in men, and
higher odds of consuming antidepressants, and hypnotics/
sedatives were found in younger individuals. These find-
ings are consistent with previous literature suggesting that
recessions can be particularly damaging for the mental
health of working age men [12, 15, 42]. It has been argued
that, during periods of economic recession, the deterior-
ation of mental health outcomes is likely to be associated
with individual-level economic shocks (e.g., job and in-
come loss), which men are more likely to experience com-
pared to women [15, 20, 22]. Contributing factors may
include shifts in labour markets [15], the disproportionate
loss of jobs among men, poor job satisfaction, and an unsat-
isfactory atmosphere at work [43, 44]. A more pronounced
pressure to assume traditional role of breadwinners and for
relative socioeconomic success, during a period in life when
one may not be fully established in the labour market, of-
fers some additional explanation on why unemployment
and uncertainty about the future may have a stronger
Table 3 Estimates of the use of psychotropic drugs obtained





























≥ 50 at baseline 1.85 1.23–2.79**
Year 2009, gender men and age 18–49 at baseline considered as reference
categories across all models
All analysis adjusted for education
** p < 0.01
*** p < 0.001
Table 4 Estimates of the interaction effects of gender and year







18–49 at baseline*2015 1.95 1.32–2.90*






18–49 at baseline*2015 1.68 1.05–2.68*






18–49 at baseline*2015 1.59 0.96–2.65






18–49 at baseline*2015 2.16 1.34–3.47*
≥ 50 at baseline*2015 1.25 0.78–2.01
Year 2009 considered as reference category across all models
All analysis adjusted for education
*confidence interval does not contain value 1
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impact on men’s mental health in recessions [45]. This is
particularly important because mental health care
utilization patterns differ by gender and seeking help for
emotional problems appears to be a more important pre-
dictor for the use of psychotropic drugs than a formal DSM
diagnosis [39]. Consequently, gender differences in mental
health treatment and prescription appropriateness may
widen during periods of economic recession, and previous
research has shown that men confronted with high job
strain used anxiolytics significantly more often than women
in similar conditions [26].
Regarding age, the greater increase in prescription
drugs utilization between both periods among the youn-
ger age group may suggest their increased vulnerability
to the economic recession and associated risk factors.
Younger workers are exposed to more precarious em-
ployment, defined as employment relations characterized
by high uncertainty, low income, and reduced social
benefits and statutory entitlements [46]. Employment in-
security is associated with poorer mental health [47] and
higher probability of psychotropic drugs prescription
[46]. Younger individuals were also disproportionately
affected by unemployment during the recession in
Portugal, with youth unemployment rates of almost 40%
in 2014 [48]. Economically inactive groups such as stu-
dents may also have had a deterioration of their living
conditions. Furthermore, young individuals may adopt
worse coping strategies to deal with adverse events, with
the use of medication being a coping mechanism in
times of uncertainty [43] or a compensatory health be-
haviour in the face of hardship [17].
Several limitations should be acknowledged when
interpreting the findings. First, the results were based on
self-reported use of psychotropic drugs, which could be
subject to recall bias or have been over-reported by one
gender or age group compared to the other. Second, the
presence of a clinical diagnosis and the appropriateness
of prescription were not evaluated, and psychotropic
drugs may have been used without a formal DSM diag-
nosis, for a wide range of emotional problems, or pa-
tients with mental disorders may not have been treated
with psychotropic drugs [39–41]. Third, the assessment
of age through a dichotomous variable was necessary
due to the number of individuals in the study but limits
the interpretation of results due to the heterogeneity of
both groups. Lastly, the analyses did not include terms
to account for time trends in drug prescription and/or
the net effect of cost-containment pharmaceutical sector
policies implemented during recession [11, 28], and it is
not possible to state that there was an acceleration in
the rate of increase in utilization seen in past decades,
nor if this increase was specific to psychotropic drugs.
Despite these limitations, research on the impact of
the economic recession on the use of psychotropic drugs
is still scarce, and the findings of this study present an
innovative contribution to the literature by comparing
self-reported consumption of psychotropic drugs, by fol-
lowing the same individuals before and after the eco-
nomic recession, as well as by assessing differences
according to gender and age. Additionally, the time-
period of evaluation, which covered the previous 12
months, instead of point or 1- to 2-week prevalence used
in most studies, allows to reduce the misclassification of
those exposed to treatment, by including both regular
users and those discontinuing therapy [26]. This is par-
ticularly important for gender comparisons, as women
are more likely than men to discontinue treatment in
difficult socioeconomic situations [26].
Conclusions
This study adds to the literature by examining the im-
pact of the 2008/2009 economic recession on the use of
psychotropic drugs according to gender and age in
Portugal. In line with the existing research, an increase
in psychotropic drugs utilization during the period of
economic recession was found, with a disproportionate
impact on men and younger individuals.
The findings, particularly the increase in the use of
hypnotics/sedatives, constitute a public health concern
given the already high consumption levels in the coun-
try, their limited therapeutic value, and the potential
problems of dependence and tolerance. This highlights
the importance of defining best prescribing practice rec-
ommendations and to invest in psychosocial interven-
tions [49, 50]. Further research is needed to better
understand the adequacy of prescribing patterns in
Portugal and to design effective public health and labour
market policies to mitigate the impact of economic re-
cessions, particularly among vulnerable groups.
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